Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SNCA | P37840 | 2/20 | 0.60 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22150197 | 0.81 | MAPT (0.56) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL20004279 | 0.79 | SNCA (0.68) | MAPTSNCARIPK1DAO | |
| SCHEMBL20005138 | 0.79 | SNCA (0.72) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL13732919 | 0.78 | MAPT (0.51) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL3155901 | 0.78 | DAO (0.54) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL21147053 | 0.77 | SNCA (0.69) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL22537818 | 0.77 | SNCA (0.61) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL20004547 | 0.77 | MAPT (0.58) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL20005072 | 0.76 | SNCA (0.68) | MAPTSNCARIPK1DAOCCNB2 | |
| SCHEMBL20004389 | 0.76 | SNCA (1.00) | MAPTSNCARIPK1DAOCCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | claimed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | claimed |
| US-20220389487-A1 | Optical Instruments and Systems for Forensic DNA Quantitation | ANDE CORPORATION (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2022223015-A1 | SIRNA TARGETING 17Β-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | 上海拓界生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022206946-A1 | SIRNA AGAINST HEPATITIS B VIRUS, AND SIRNA CONJUGATE | 上海拓界生物医药科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-20220315996-A1 | Optical Instruments and Systems for Forensic DNA Quantitation | ANDE CORPORATION (US) | 2022-10-06 | — | — | US | disclosed |
| US-11441173-B2 | Optical instruments and systems for forensic DNA quantitation | ANDE CORPORATION (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3587594-B1 | PARTICLE-ASSISTED NUCLEIC ACID SEQUENCING | HARVARD COLLEGE (US) | 2022-04-13 | — | — | EP | disclosed |
| US-10900038-B2 | siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof | APPLIED BIOSYSTEMS, LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200248243-A1 | Methods for Forensic DNA Quantitation | ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP | 2020-08-06 | — | — | US | disclosed |
| WO-2009085215-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009039173-A2 | SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF | APPLIED BIOSYSTEMS INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-1994182-A2 | DEGENERATE NUCLEOBASE ANALOGS | Siemens Healthcare Diagnostics Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070259827-A1 | Compositions and methods for enhancing discriminatory RNA interference | UNIVERSITY OF MASSACHUSETTS (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007106690-A2 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007087451-A2 | COMPOSITIONS AND METHODS FOR ENHANCING DISCRIMINATORY RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | DTYMK, UNG, TPR | MAPT 2111/4885SNCA 2104/4885RIPK1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.